Cesca Therapeutics Inc (NASDAQ:KOOL) has announced that it has been granted a third patent, by the USPTO, for its SurgWerks platform. The technology makes use of proprietary methods for treating ischemic cardiovascular diseases. The third patent specifically relates to the cell compositions and methods, used in the platform, for rapid delivery. The director of clinical research at the company, Dalip Sethi Ph.D, stated that the new patent covers the critical methods used for rapid infusion of bone marrow stem cells and progenitor cells. He claimed that this was an integral part their proprietary platform.

Dr. Sethi also voiced his view that the growing number of patents associated with SurgWerks, underpins their approach to treatment of cardiovascular diseases, with the latest procedures. It should be noted here that Cesca’s technology for storage and concentration of umbilical cord derived blood stem cells already holds over 30 patents. As such, the company believes that it can build a similar patent portfolio for its bone marrow derived stem cell treatments.

Cesca’s SurgWerks system is currently under development, but is expected to host devices, indication specification SurgWerks kits and analytics, to be used in regenerative stem cell therapy. Moreover, the company is also developing a CellWerks system, which is focused on the preparation of adult stem cells, from blood or bone marrow of the patient. This system would also host associated analytics, for intra-laboratory preparation. In addition to this, KOOL also has systems for the disposal and storage of these stem cells.

Earlier in September, KOOL issued its financial results for the 4Q2016, recording revenues of $3 million, $0.7 million lower than that of the preceding year. The company stated that this was mainly due to a decline in BioArchive device sales. Added to this, ResQ had also been withdrawn from the market last year, resulting in lower revenue. As such, the net loss for the 4Q2016 widened to $3.7 million, from $2.4 million a year ago.

Cesca Therapeutics Inc (NASDAQ:KOOL) had a trade volume of 6.57 million and gained 23.42%, during the October 24 trading session, to close at a share price of $3.9.

Previous articleAdvanced Micro Devices, Inc. (NASDAQ:AMD) Makes An Impressive Comeback
Next articleGold Fields Limited (ADR) (NYSE:GFI) Plans To Reinvest In Damang Mine As Production Declines
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.